Stem cell transplantation for the management of primary systemic amyloidosis.
about
Amyloidosis and POEMS syndrome.Amyloidosis of the head and neck: a clinicopathological study of cases with long-term follow-up.Primary systemic amyloidosis presenting as idiopathic inflammatory colitisAmyloid in the cardiovascular system: a reviewHigh-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.Treatment options for POEMS syndrome.AL cardiac amyloidosis and arterial thromboembolic events.Response of hemorrhagic bullous skin lesions of the breast secondary to primary systemic amyloidosis to a five-drug combination chemotherapy: a case report and review of the literatureAutologous stem cell transplantation and IgM amyloidosis.An unusual case of cardiac amyloidosisRevised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.AL amyloidosis manifesting as systemic lymphadenopathy.Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosisCurrent status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.Bladder dysfunction in peripheral neuropathies.The clinical approach to autonomic failure in neurological disorders.Heart transplantation in cardiac amyloidosis.Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.Autologous stem cell transplant for Al amyloidosis.Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic Al amyloidosis.Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients.High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.Two cases with hepatic amyloidosis suspected of having primary sclerosing cholangitis.The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan.Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement.Two Cases of Gastric and Esophageal Amyloidosis.Outcome of autologous stem cell transplantation for AL amyloidosis in the UK
P2860
Q33867198-5EF0D7C7-D8B5-4202-9613-9568B0F66DEFQ34247202-6753EE15-C37C-449C-85CA-BE2040DD51C2Q35296249-BFD5B4D8-E180-4197-AC80-C9FFB96263A2Q35588349-6DBDDA2A-D91C-4139-9322-6E945A83B276Q35750326-5B89BE1D-FA6B-4BD4-B8DB-059D5BFD4CF1Q35848844-9A5928EA-FE88-43FA-BEE4-97B821A0C701Q36161268-15AD0308-3479-461C-8374-FA10B8CDEE39Q36272786-A0BA2DD5-2B43-4F54-BA01-3F32D8EC5C19Q36444507-39E1AF8D-C4C2-4262-8817-49E8AA3599DBQ36535491-2F9FF324-CF87-45A9-B3A4-2181F66553EEQ36796940-DF65BD90-A264-4EAD-9EA4-0C0C0D0C5164Q36910372-FCA9CC4F-AB7C-4123-B204-175C299B43F6Q37165349-1C678BF7-3B7E-43EF-854D-663C56453BE9Q37172003-A3820E7F-5067-488F-AC6F-9E2B70704661Q37904673-E971842A-5826-4F1C-B9FA-DD59606220AAQ37970651-FA31B245-D713-4291-B6D2-E5A8D3B7F198Q38215382-05A8E987-11F4-440D-AA13-BC91BDB8F6B3Q39172346-7F065483-BE15-4393-AF0D-FF089C6D9A3EQ40973226-06E416E2-8103-4DD8-A082-24AEDBE453A2Q42179759-BEEAAA22-8C8B-46CD-A7F1-C5AD076D22D1Q42932124-83594389-A703-4A15-B038-04A8A8F127AFQ43583135-284AFB6F-D770-4409-8C60-02A30765EB41Q45164371-AB8B3782-6FA3-4580-9DA6-7F01F16065EEQ45872600-0A873F84-53B0-43C4-ACD8-9FD62F766448Q47602198-6CF0E152-6652-429C-A3C8-275BCF368719Q47646067-9B72597D-3199-4328-B1F3-7D12E5D38487Q48382207-E1DF1434-CD9F-46BE-B9D4-2FFE54AD9F82Q53504425-89625285-AAAF-4071-906A-62C8B82000EEQ53671959-61F89CB4-222B-4327-9E7C-7490DE0D2731Q55533445-2C3D0002-F6AF-4258-ADA8-685C65E8C59CQ58853185-FC7D39A7-8DC0-4B22-B788-54C73B41FB4E
P2860
Stem cell transplantation for the management of primary systemic amyloidosis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Stem cell transplantation for the management of primary systemic amyloidosis.
@ast
Stem cell transplantation for the management of primary systemic amyloidosis.
@en
type
label
Stem cell transplantation for the management of primary systemic amyloidosis.
@ast
Stem cell transplantation for the management of primary systemic amyloidosis.
@en
prefLabel
Stem cell transplantation for the management of primary systemic amyloidosis.
@ast
Stem cell transplantation for the management of primary systemic amyloidosis.
@en
P2093
P50
P1476
Stem cell transplantation for the management of primary systemic amyloidosis.
@en
P2093
David J Inwards
Dennis A Gastineau
Ivana N M Micallef
Mark R Litzow
Michael G Chen
Stephen M Ansell
P304
P356
10.1016/S0002-9343(02)01208-1
P407
P577
2002-11-01T00:00:00Z